[Federal Register Volume 75, Number 232 (Friday, December 3, 2010)]
[Notices]
[Page 75498]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-30358]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec.  1301.33(a), Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on July 8, 2010, Agilent 
Technologies, 25200 Commercentre Drive, Lake Forest, California 92630-
8810, made application by letter to the Drug Enforcement Administration 
(DEA) to be registered as a bulk manufacturer of the basic classes of 
controlled substances listed in schedule II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Phencyclidine (7471).......................  II
1-piperidinocyclohex-......................  II
anecarbonitrile (8603).....................
Benzoylecgonine (9180).....................  II
------------------------------------------------------------------------

    The company plans to manufacture small quantities of the listed 
controlled substances for use in diagnostic products.
    Agilent Technologies submitted this application because, effective 
May 14, 2010, Varian, Inc., located at 25200 Commercentre Drive, Lake 
Forest, California 92630-8810, became a wholly-owned subsidiary of 
Agilent Technologies. Varian, Inc.'s legal existence as a corporation 
and as a DEA registrant as a bulk manufacturer will eventually cease 
and Agilent Technologies will take over all of Varian Inc.'s activities 
with regard to controlled substances, requiring possession of a DEA 
registration as a bulk manufacturer issued to Agilent Technologies. 
Presently, Agilent Technologies' activities with regard to controlled 
substances will be exactly the same as performed by Varian, Inc.
    Any other such applicant, and any person who is presently 
registered with DEA to manufacture such substances, may file comments 
or objections to the issuance of the proposed registration pursuant to 
21 CFR Sec.  1301.33(a).
    Any such written comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than February 1, 2011.

    Dated: November 18, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2010-30358 Filed 12-2-10; 8:45 am]
BILLING CODE 4410-09-P